Abstract: The present inventors have carried out intensive screening of a new type compound which inhibits the P2X2/3,3 receptor and found as a result that minodronic acid as a bisphosphonate having bone resorption inhibitory action shows excellent P2X2/3,3 receptor inhibitory action and can be used as a preventive or therapeutic agent for various pains, thus accomplishing the invention. That is, the invention relates to a P2X2/3,3 receptor inhibitor, particularly an analgesic, which comprises minodronic acid or a salt thereof as the active ingredient. Since the “P2X2/3 and/or P2X3 receptor inhibitor” of the invention inhibits the function of P2X2/3,3 receptor known as a molecule which is concerned in various pains consisting of nociceptive pain, inflammatory pain and neurogenic pain, it is useful for the prevention or treatment of various pains in which the P2X2/3,3 receptor is concerned in the pain transduction.